Search by Drug Name or NDC

NDC 00023-6501-30 UBRELVY 100 mg/1 Details

UBRELVY 100 mg/1

UBRELVY is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Allergan, Inc.. The primary component is UBROGEPANT.

MedlinePlus Drug Summary

Ubrogepant is used to treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Ubrogepant is in a class of medications called calcitonin gene-related peptide receptor antagonists. It works by blocking the action of a certain natural substance in the body that causes migraine headaches. Ubrogepant does not prevent migraine attacks or reduce the number of headaches you have.

Related Packages: 00023-6501-30
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ubrogepant

Product Information

NDC	00023-6501
Product ID	0023-6501_a2a2dac4-01bf-469c-be05-60bee5d4b117
Associated GPIs	67701080000340
GCN Sequence Number	080589
GCN Sequence Number Description	ubrogepant TABLET 100 MG ORAL
HIC3	H3F
HIC3 Description	ANTIMIGRAINE PREPARATIONS
GCN	47478
HICL Sequence Number	046273
HICL Sequence Number Description	UBROGEPANT
Brand/Generic	Brand
Proprietary Name	UBRELVY
Proprietary Name Suffix	n/a
Non-Proprietary Name	ubrogepant
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	TABLET
Route	ORAL
Active Ingredient Strength	100
Active Ingredient Units	mg/1
Substance Name	UBROGEPANT
Labeler Name	Allergan, Inc.
Pharmaceutical Class	Calcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA211765
Listing Certified Through	2024-12-31

Package

NDC 00023-6501-30 (00023650130)

Pricing Information	N/A
NDC Package Code	0023-6501-30
Billing NDC	00023650130
Package	30 PACKET in 1 BOX (0023-6501-30) / 1 TABLET in 1 PACKET (0023-6501-02)
Marketing Start Date	2019-12-23
NDC Exclude Flag	N